Clinical trial · Interventional
Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents
Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse
NCT00147160CI-TRIAL-00006698completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the combination of Temozolomide and Cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Temozolomide, Cisplatinum | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Radiological response after two courses of Temozolomide-Cisplatinum
Secondary outcomes (3)
- measure
- Progression-free survival
- measure
- Health status and quality of life
- measure
- Toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 4 Years
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Age from 4th birthday and younger than 21st birthday * Histologically documented malignant glial tumour (WHO classification grade III and IV) : astrocytoma, oligodendroglioma, oligoastrocytoma and mixed tumours * Measurable and evaluable disease by the imaging criteria (MRI) * Patient not previously treated by either of the two drugs Exclusion Criteria: * Malignant brain stem tumours are excluded
References
Publications (0)
Data not yet available
No reference posted for this study.